Search Result

Results for "

NLRP3+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (4) ATTECs (1) Autophagy (2) Caspase (5) CDK (2) COX (1) Cytochrome P450 (2) Interleukin Related (18) NEKs (2) NF-κB (7) NO Synthase (1) NOD-like Receptor (NLR) (72) p38 MAPK (2) PI3K (2) Potassium Channel (1) Pyroptosis (6) Reactive Oxygen Species (ROS) (1) Reference Standards (4) STAT (1) TNF Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (67) Metabolic Disease (4) Neurological Disease (14)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12815

MCC950 Maximum Cited Publications 453 Publications Verification CP-456773; CRID3	NOD-like Receptor (NLR)	Inflammation/Immunology
MCC950 (CP-456773; CRID3) is a potent and selective *NLRP3* inhibitor with IC₅₀s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

HY-12815A

MCC950 sodium Maximum Cited Publications 453 Publications Verification CP-456773 sodium; CRID3 sodium salt	NOD-like Receptor (NLR)	Inflammation/Immunology
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective *NLRP3* inhibitor with IC₅₀s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

HY-N3005

Britannin 1 Publications Verification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology Cancer
Britannin is an *NLRP3* inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the *NLRP3* inflammasome by blocking the interaction between *NLRP3* and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics ^[3] .

HY-155876

NVP-DFV890 NLRP3 antagonist 2	NOD-like Receptor (NLR)	Infection Inflammation/Immunology
NVP-DFV890 is an orally administered, selective *NLRP3* inhibitor. NVP-DFV890 directly binds to *NLRP3, blocks maturation of pro-inflammatory cytokines IL-1β* and IL-18, and inhibits pyroptotic cell death. NVP-DFV890 acts as an inducer of viral clearance, promoting earlier clearance of SARS-CoV-2. NVP-DFV890 can be used for the research of COVID-19 pneumonia and coronavirus-associated acute respiratory distress syndrome (CARDS) .

HY-103666

CY-09 45+ Cited Publications	NOD-like Receptor (NLR)	Inflammation/Immunology
CY-09 is a selective and direct *NLRP3* inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .

HY-162877

AZD4144	NOD-like Receptor (NLR) Interleukin Related Potassium Channel	Inflammation/Immunology
AZD4144 is an orally active *NLRP3* inhibitor (EC₅₀: 0.082 μM). AZD4144 effectively inhibits the release of IL-1β when NLRP3 is overactivated, exerting an anti-inflammatory effect. AZD4144 has low inhibitory effect on hERG and low cardiotoxicity. AZD4144 has the potential to study diseases and conditions associated with NLRP3 inflammasome activation .

HY-N1431

Tabersonine 3 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Inflammation/Immunology Cancer
Tabersonine is a selective, orally active *NLRP3* inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, *PI3K/Akt, and p38 MAPK* signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer ^[3].

HY-148258

GDC-2394	NOD-like Receptor (NLR) Interleukin Related Caspase	Neurological Disease Inflammation/Immunology
GDC-2394 is an orally active and selective *NLRP3* inhibitor, and also inhibits IL-1β with IC₅₀s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation. GDC-2394 could be used to study gouty arthritis.

HY-101868

INF39 10+ Cited Publications	NOD-like Receptor (NLR)	Inflammation/Immunology
INF39 is an irreversible and noncytotoxic *NLRP3* inhibitor.

HY-163159

NP3-562	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
NP3-562 is an orally active *NLRP3* Inhibitor. NP3-562 inhibits IL-1β release in the supernatant of Nigericin (HY-127019)-stimulated THP-1 cells (IC₅₀ = 66 nM), human whole blood (IC₅₀ = 214 nM) and a mouse acute peritonitis model. NP3-562 can be used for the study of acute peritonitis .

HY-171820

NLRP3-IN-80	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-80 (Compound 1) is an *NLRP3* inhibitor that can be used for the study of inflammaging .

HY-161297A

NT-0249 free base	NOD-like Receptor (NLR)	Inflammation/Immunology
NT-0249 free base is an orally active *NLRP3* inhibitor. NT-0249 has anti-inflammatory activity .

HY-163358

SLC3037 1 Publications Verification	NOD-like Receptor (NLR) NEKs	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SLC3037 is a *NLRP3* inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .

HY-164304

INF 195	Pyroptosis Interleukin Related NOD-like Receptor (NLR)	Cardiovascular Disease Inflammation/Immunology
INF 195 is an *NLRP3* inhibitor. INF 195 can inhibit *NLRP3* driven macrophage pyroptosis and IL-1β release, with an EC₅₀ value of 0.15 μM. INF 195 can reduce the infarct size of isolated mouse hearts at low doses, effectively preventing myocardial ischemia/reperfusion injury .

HY-150206

NLRP3-IN-13	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
NLRP3-IN-13 (Compound C77 in reference patent) is a selective and potent *NLRP3* inhibitor (IC₅₀: 2.1 μM). NLRP3-IN-13 inhibits NLRP3 andNLRC4 inflammasomes, and inhibits NLRP3-mediated IL-1β production. NLRP3-IN-13 also inhibits NLRP3 ATPase activity. NLRP3-IN-13 can be used in the research of neuroinflammatory disorders .

HY-174270

NLRP3-IN-79	NOD-like Receptor (NLR) Interleukin Related NEKs	Inflammation/Immunology
NLRP3-IN-79 is an orally active *NLRP3* inhibitor. NLRP3-IN-79 inhibits *NLRP3* inflammasome with an IC₅₀ of 10.69 nM. NLRP3-IN-79 blocks NLRP3 inflammasome assembly by directly binding to *NLRP3* and disrupting the *NEK7-NLRP3* interaction. NLRP3-IN-79 can be used for the study of NLRP3-driven diseases model, including systemic inflammation, peritonitis, and colitis .

HY-175278

BAL-1516	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
BAL-1516 is an orally active *NLRP3* inhibitor with human *NLRP3* K_d of 14.2 nM, mouse *NLRP3* K_d of 200 nM, and blood-brain barrier penetration.BAL-1516 binds to a surface groove of the *NLRP3* nucleotide-binding domain, contacts FISNA and WHD subdomains, forms three hydrogen bonds to the peripheral β-strand of the triple-ATPase, and does not alter *NLRP3* ATP-hydrolysis activity.BAL-1516 shows specificity for *NLRP3* over other NOD-like receptors, directly binds mouse *NLRP3, and inhibits* inflammasome formation in monocytes and microglia .

HY-161297

NT-0249	NOD-like Receptor (NLR)	Inflammation/Immunology
NT-0249 is an orally active *NLRP3* inhibitor. NT-0249 has anti-inflammatory activity

HY-146765

AMS-17	NOD-like Receptor (NLR)	Neurological Disease Inflammation/Immunology
AMS-17 is a potent *NLRP3* inhibitor, inhibiting microglia activation in vitro and in vivo. AMS-17 also inhibits cytokines such as caspase-1, TNF-α, IL-1β and inducible nitric oxide synthase (iNOS) in N9 cells. AMS-17 can be used for researching inflammation-associated neurological disorders, such as vascular dementia (VaD) .

HY-162588

MC-ND-18	NOD-like Receptor (NLR) ATTECs Autophagy	Inflammation/Immunology
MC-ND-18 is an ATTEC degrader that degrades *NLRP3* via the Autophagy pathway, with a DC₅₀ of 125.5 nM in THP-1 cells. MC-ND-18 exhibits anti-inflammatory activity in a DSS-induced mouse model of colitis. MC-ND-18 can be used for research on inflammatory bowel disease. MC-ND-18 consists of an NLRP3 inhibitor (HY-156121), a linker (HY-W018745), and an LC3 ligand .

HY-155463

NLRP3-IN-25	NOD-like Receptor (NLR) Interleukin Related	Inflammation/Immunology
NLRP3-IN-25 (compound 32) is an orally available *NLRP3* inhibitor with anti-inflammatory activity. NLRP3-IN-25 attenuates renal injury in doxorubicin-induced glomerulonephritis in mice. NLRP3-IN-25 inhibits IL-1β secretion in THP-1 cells with an IC₅₀ of 21 nM .

HY-N1431A

Tabersonine hydrochloride 3 Publications Verification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK	Neurological Disease Inflammation/Immunology
Tabersonine hydrochloride is a selective, orally active *NLRP3* inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, *PI3K/Akt, and p38 MAPK* signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer ^[3].

HY-177128

Sebrinoflast	NOD-like Receptor (NLR)	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Sebrinoflast (Compound 5) is a *NLRP3* inhibitor with an IC₅₀ ≤1  μM for hNLRP3. Sebrinoflast can be used for inflammatory and cardiovascular diseases including NASH and atherosclerosis and neurological diseases like Alzheimer's disease research .

HY-179024

NP3-742	NOD-like Receptor (NLR) Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
NP3-742 is an orally active *NLRP3* inhibitor that binds to the NLRP3 NACHT domain. NP3-742 inhibits IL-1β release with IC₅₀s of 6 nM and 47 nM in both the cellular and whole blood assays, respectively. NP3-742 is highly selective against a panel of more than 50 enzymes, receptors and sodium and calcium channels. NP3-742 can be used for the study of gout, cardiovascular disease or osteoarthritis .

HY-170537

NLRP3-IN-67	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-67 (compound 42) is a potent NLRP3 inhibitor .

HY-153554

NLRP3-IN-18	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-18 (compound 13) is a potent *NLRP3* inhibitor with an IC₅₀ value of ≤1.0 µM .

HY-156469

NLRP3-IN-22	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-22 (Compound II-4) is a *NLRP3* inhibitor (inhibition rate: 67% at 10 μM)

HY-179132

TN-101	NOD-like Receptor (NLR)	Metabolic Disease Inflammation/Immunology
TN-101 is an orally active *NLRP3* inhibitor (IC₅₀ = 29.8 nM). TN-101 can be used for the study of obesity .

HY-N9921

Antcin A	Pyroptosis NOD-like Receptor (NLR)	Inflammation/Immunology
Antcin A is a potent *NLRP3* inhibitor that inhibits the assembly and activation of the *NLRP3* inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .

HY-159159

MS-II-124	NOD-like Receptor (NLR)	Inflammation/Immunology
MS-II-124 is an effective and selective *NLRP3* inhibitor (IC₅₀=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .

HY-158093

NIC-12	NOD-like Receptor (NLR)	Inflammation/Immunology
NIC-12 is a potent *NLRP3* inhibitor. NIC-12 selectively reduces circulating IL-1ß levels in the LPS-endotoxemia mice model. NIC-12 inhibits NLRP3 inflammasome activation in mouse macrophages .

HY-12815R

MCC950 (Standard) CP-456773 (Standard); CRID3 (Standard)	NOD-like Receptor (NLR) Reference Standards	Inflammation/Immunology
MCC950 (Standard) is the analytical standard of MCC950. This product is intended for research and analytical applications. MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.

HY-N10312

Yadanzigan YDZG	NOD-like Receptor (NLR) NF-κB Reactive Oxygen Species (ROS)	Inflammation/Immunology
Yadanzigan (YDZG) is an anti-inflammatory agent and a *NLRP3* inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice .

HY-146802

NLRP3-IN-9	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-9 is a potent *NLRP3* inhibitor. NLRP3-IN-9 inhibits IL-1β release. NLRP3-IN-9 reduces inflammation and mechanical hyperalgesia. NLRP3-IN-9 has the potential for the research of gout .

HY-163695

NLRP3-IN-41	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant *NLRP3* inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research .

HY-172788

NLRP3-IN-78	Pyroptosis NF-κB	Inflammation/Immunology
NLRP3-IN-78 (compound 21) is a *NLRP3* inhibitor with the inhibition rate of 46.72% in GSDMD-induced pyroptosis at 5 μM. NLRP3-IN-78 binds to the NLRP3 protein and inhibits GSDMD-NT oligomerization. NLRP3-IN-78 also inhibits GSDMD cleavage, and upstream NF-κB signaling, demonstrating its anti-inflammatory activity .

HY-172941

VEN-02XX	NOD-like Receptor (NLR)	Neurological Disease
VEN-02XX is an orally active and brain-permeable *NLRP3* inhibitor. VEN-02XX inhibits the release of IL-1β and IL-18 (IC₅₀ 0.3 and 0.28 μM, respectively). VEN-02XX restores memory and cognition, inhibits microgliosis, and reduces neuroinflammation and tau pathology in the 5XFAD/Rubicon KO mouse model. VEN-02XX may be used in the study of Alzheimer's disease (AD) .

HY-179429

NLRP3-IN-85	NOD-like Receptor (NLR) TNF Receptor Interleukin Related	Inflammation/Immunology
NLRP3-IN-85 (compound 5d) is a potent *NLRP3* inhibitor that targets mitochondria in a ΔΨm-independent manner. NLRP3-IN-85 protects mitochondria from oxidative stress and inflammation damage and suppresses key inflammatory factors (NO, TNF-α, IL-6). NLRP3-IN-85 relives acute lung injury in mice and inhibits paw edema in rats. NLRP3-IN-85 can be used for acute lung injury (ALI) research .

HY-162980

NLRP3-IN-52	NOD-like Receptor (NLR)	Cancer
NLRP3-IN-52 (compund 1) is a *NLRP3* inhibitor .

HY-170536

NLRP3-IN-66	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-66 (example 257) is a potent NLRP3 inhibitor .

HY-170535

NLRP3-IN-65	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-65 (compound 41) is a potent NLRP3 inhibitor .

HY-178125

JNJ-79883960	NOD-like Receptor (NLR)	Inflammation/Immunology
JNJ-79883960 is a *NLRP3* inhibitor. JNJ-79883960 can be used for the study of inflammation.

HY-163493

NLRP3-IN-35	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-35 (compound 11) is an *NLRP3* inhibitor (IC₅₀ < 1 μM) .

HY-162992

NLRP3-IN-53	NOD-like Receptor (NLR)	Cancer
NLRP3-IN-53 (compund 1) is a *NLRP3* inhibitor with an IC₅₀ of 3.4 nM .

HY-163494

NLRP3-IN-36	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-36 (Compound 111) is an *NLRP3* inhibitor (IC₅₀ <1 μM) .

HY-160545

NLRP3-IN-31	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-31 (Comp 14) is a *NLRP3* inhibitor, with an IC₅₀ of 0.3-0.5 μM .

HY-169188

NLRP3-IN-50	NOD-like Receptor (NLR)	Cancer
NLRP3-IN-50 (compound SN3-1) is a potential NLRP3 inhibitor with therapeutic potential for inflammatory diseases. .

HY-161120

NLRP3-IN-27	NOD-like Receptor (NLR)	Inflammation/Immunology
NLRP3-IN-27 is a selective *NLRP3* inhibitor with a IC₅₀ value of 0.55 μM. NLRP3-IN-27 can be used in the study of inflammation and immunity .

HY-162013

NLRP3-IN-26	NOD-like Receptor (NLR) Pyroptosis	Inflammation/Immunology
NLRP3-IN-26 (compound 15Z) is a *NLRP3* inhibitor with the IC₅₀ of 0.13 μM. NLRP3-IN-26 can be used for DSS-induced colitis model study .

HY-157554

ZM640	NOD-like Receptor (NLR)	Inflammation/Immunology
ZM640 is a *NLRP3* inhibitor. ZM640 enhances IL-1β release mediated by NLRP3 inflammasome activation in THP-1 cells. ZM640 shows low cytotoxicity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N3005

Britannin 1 Publications Verification	Phyllodium pulchellum (L.) Desv. Classification of Application Fields Terpenoids Sesquiterpenes Plants Compositae Inflammation/Immunology Disease Research Fields Source Classification	Apoptosis Autophagy NOD-like Receptor (NLR) Pyroptosis
Britannin is an *NLRP3* inhibitor with an IC₅₀ of 3.630 μM, exhibiting anti-inflammatory activity. Britannin inhibits the activation and assembly of the *NLRP3* inflammasome by blocking the interaction between *NLRP3* and NEK7. Additionally, Britannin demonstrates antitumor activity by inhibiting the proliferation of tumor cells through blocking the interaction between HIF-1α and Myc, thereby suppressing PD-L1 expression and enhancing cytotoxic T lymphocyte activity. Britannin can also induce apoptosis and autophagy in liver cancer cells by activating ROS-regulated AMPK. Britannin holds promise for research in the fields of anti-inflammatory and antitumor therapeutics ^[3] .

HY-N1431

Tabersonine 3 Publications Verification	Apocynaceae Alkaloids Structural Classification Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine is a selective, orally active *NLRP3* inhibitor. Tabersonine directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, *PI3K/Akt, and p38 MAPK* signaling pathways. Tabersonine can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer ^[3].

HY-N1431A

Tabersonine hydrochloride 3 Publications Verification	Apocynaceae Alkaloids Plants Indole Alkaloids Catharanthus roseus (L.) G. Don Source Classification	NOD-like Receptor (NLR) Apoptosis Cytochrome P450 NF-κB PI3K Akt CDK Caspase Interleukin Related p38 MAPK
Tabersonine hydrochloride is a selective, orally active *NLRP3* inhibitor. Tabersonine hydrochloride directly binds to the NACHT domain of NLRP3, inhibiting its ATPase activity and oligomerization, thereby blocking ASC spot formation and caspase-1 activation, and reducing the release of pro-inflammatory cytokines such as IL-1β. Tabersonine hydrochloride also inhibits K63-linked ubiquitination of TRAF6, blocking NF-κB, *PI3K/Akt, and p38 MAPK* signaling pathways. Tabersonine hydrochloride can inhibit inflammatory responses, induce apoptosis of liver cancer cells through mitochondrial pathways and death receptor pathways, reduce mitochondrial membrane potential, promote cytochrome c release, and activate caspase proteins. Tabersonine hydrochloride is mainly used in the study of NLRP3-driven inflammatory diseases (such as acute lung injury, sepsis, peritonitis) and tumors such as liver cancer ^[3].

HY-N9921

Antcin A	Structural Classification Microorganisms Steroids Source Classification	Pyroptosis NOD-like Receptor (NLR)
Antcin A is a potent *NLRP3* inhibitor that inhibits the assembly and activation of the *NLRP3* inflammasome. Antcin A can inhibit Kupffer cell pyroptosis and has liver protective activity. Antcin A can be used to study inflammation, such as non-alcoholic fatty liver disease .

HY-N10312

Yadanzigan YDZG	Natural Products Simaroubaceae Plants Brucea javanica (L.) Merr. Source Classification	NOD-like Receptor (NLR) NF-κB Reactive Oxygen Species (ROS)
Yadanzigan (YDZG) is an anti-inflammatory agent and a *NLRP3* inhibitor. Yadanzigan specifically inhibits NLRP3 activation via inhibiting NF-κB pathway and Reactive Oxygen Species production. Yadanzigan also moderates LPS (HY-D1056)-induced acute lung injury (ALI) in mice .

Cat. No.	Product Name		Classification

HY-159159

MS-II-124		Alkynes
MS-II-124 is an effective and selective *NLRP3* inhibitor (IC₅₀=0.12 μM) with anti-inflammatory and immunomodulatory activities, which can be used in the research of acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

NLRP3+inhibitor

Inhibitors & Agonists

NaturalProducts

Click Chemistry

Natural
Products